Maria Re to Anti-HIV Agents
This is a "connection" page, showing publications Maria Re has written about Anti-HIV Agents.
Connection Strength
0.765
-
Impact of Different Antiretroviral Strategies on Total HIV-DNA Level in Virologically Suppressed HIV-1 Infected Patients. Curr HIV Res. 2017; 15(6):448-455.
Score: 0.266
-
Discordant resistance interpretations in multi-treated HIV-1 patients. Int J Antimicrob Agents. 2005 Mar; 25(3):211-5.
Score: 0.117
-
Conflicting interpretations of the prevalence of mutations associated with drug resistance in antiviral naïve HIV-1 patients with acute and chronic infection. Int J Antimicrob Agents. 2004 Feb; 23(2):164-8.
Score: 0.108
-
Simplification to dual-therapy containing lamivudine and darunavir/ritonavir or atazanavir/ritonavir in HIV-infected patients on virologically suppressive antiretroviral therapy. Infect Dis (Lond). 2018 05; 50(5):352-360.
Score: 0.071
-
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial. PLoS One. 2017; 12(11):e0187393.
Score: 0.071
-
Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study). Infect Dis (Lond). 2017 Oct; 49(10):737-747.
Score: 0.069
-
Nevirapine prophylaxis to prevent HIV-1 mother-to-child transmission: pharmacokinetic considerations in preterm infants. New Microbiol. 2016 Oct; 39(4):314-316.
Score: 0.064